1. EUCERD (The European Union Committee of Experts on Rare Diseases). Recommendation of the European Union committee of experts on rare diseases to the European Commission and the Member States on improving informed decisions based on the clinical added value of orphan medicinal products (CAVOMP) information flow. 2012. http://ec.europa.eu/health/rare_diseases/docs/eucerd_cavomp_annex_en.pdf . Accessed 06 Sep 2016.
2. European Commission. Inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products. 2015. http://ec.europa.eu/health/files/orphanmp/doc/orphan_inv_cwd_20160126.pdf . Accessed 07 Sep 2016.
3. European Commission. Orphan medicinal products. 2016. http://ec.europa.eu/health/human-use/orphan-medicines/index_en.htm . Accessed 06 Sep 2016.
4. Dupont A, Van Wilder P. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4):488–96.
5. Gutierrez L, Patris J, Hutchings A, Cowell W. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10:53.